Can You Take Allopurinol During a Gout Attack?

Allopurinol can be started during a gout attack, and current rheumatology guidelines conditionally recommend doing so rather than waiting for the flare to fully resolve. This is a relatively recent shift in clinical thinking. For decades, the standard advice was to let the acute inflammation settle before introducing any urate-lowering drug, out of concern that changing uric acid levels mid-flare would make things worse. The evidence behind that old caution was always thin, and newer trial data have pushed major guideline bodies to reverse course.

Why the Old Advice Said to Wait

A gout flare is an intense inflammatory reaction to urate crystals that have already formed in and around a joint. Those crystals trigger an immune cascade involving a protein complex called the NLRP3 inflammasome, which churns out inflammatory signaling molecules that cause the redness, swelling, and severe pain of an attack.¹ Allopurinol does nothing to quiet that inflammation. It works upstream, blocking the enzyme xanthine oxidase so less uric acid gets produced in the first place.² The fear was that rapidly dropping uric acid levels during a flare could destabilize existing crystal deposits, causing even more crystals to shed into the joint fluid and prolonging or worsening the attack.

That reasoning made intuitive sense, and it became deeply embedded in medical training. But when researchers actually tested whether starting allopurinol during a flare made pain or duration measurably worse, the feared worsening didn’t materialize in any convincing way. Guidelines from different countries have acknowledged this at different speeds, which is part of why you may still get conflicting advice depending on which doctor you see or which country you live in.³

What the Current Guidelines Actually Say

The 2020 American College of Rheumatology (ACR) guideline for gout management conditionally recommends starting urate-lowering therapy during a gout flare. The reasoning is practical: people often see a doctor because of the flare, and that visit is a chance to begin long-term treatment rather than scheduling a follow-up that many patients never attend. The guideline is conditional rather than strong because the supporting evidence, while reassuring, comes from a limited number of trials.⁴

The European League Against Rheumatism (EULAR) has taken a similar direction, although some older European guidelines still suggest waiting until the flare resolves. If your doctor tells you to wait, it doesn’t mean they’re wrong or outdated; it may reflect a regional guideline or a clinical judgment about your specific situation. But the trend among major rheumatology bodies is clearly toward starting sooner.

The Flare Paradox When Starting Allopurinol

Here is the part that catches most people off guard: starting allopurinol can itself trigger new gout flares, regardless of whether you begin during an attack or after one has resolved. This is sometimes called a “mobilization flare.” When uric acid levels drop, the chemical environment around existing crystal deposits changes. Crystals that were stable in a high-uric-acid environment begin to dissolve, and in the process they shed fragments that provoke new rounds of inflammation. It’s a frustrating and counterintuitive situation where the treatment that will eventually prevent attacks temporarily makes them more likely.

This isn’t unique to allopurinol. In a large phase III trial comparing febuxostat (another urate-lowering drug) to allopurinol, about a fifth of patients on allopurinol 300 mg daily experienced at least one gout flare during the first eight weeks, and rates were similar or higher in the febuxostat groups.⁵ A separate head-to-head study found that roughly 42% of patients starting allopurinol and 46% starting febuxostat had at least one flare during the initiation phase, with no statistically meaningful difference between the two drugs.⁶ The mobilization flare is a class effect of urate-lowering drugs, not a specific failing of allopurinol.

These early flares are one of the main reasons patients lose faith in allopurinol and stop taking it. Research into what drives adherence has found that experiencing a flare while faithfully taking the medication is a major trigger for discontinuation, especially if the patient hasn’t been warned it could happen.⁷ If your doctor doesn’t explain the mobilization flare in advance, the natural conclusion is that the drug isn’t working or is making things worse. In reality, early flares are often a sign that crystal deposits are being disrupted, which is exactly what needs to happen for long-term control.

Anti-Inflammatory Prophylaxis Makes a Big Difference

Because mobilization flares are so common and so discouraging, guidelines strongly recommend adding a low-dose anti-inflammatory drug alongside allopurinol for the first several months. The ACR guideline recommends prophylaxis for at least three to six months when starting any urate-lowering therapy.⁴ Low-dose colchicine is the most commonly used option. In a controlled trial, patients who took colchicine while starting allopurinol had dramatically fewer flares than those who didn’t: roughly half a flare on average versus nearly three flares over the same period.⁸ The flares they did experience were also milder.

A separate study looked at whether colchicine prophylaxis is still necessary when allopurinol is started at a low dose and increased very gradually, the so-called “start-low, go-slow” approach. Even with that cautious dosing strategy, patients who received colchicine still had fewer flares per month than those on placebo, averaging about 0.35 flares per month versus 0.61.⁹ That trial was designed to test whether skipping colchicine would be “non-inferior” (essentially, no worse), and it failed that test, meaning there was a real and measurable benefit to including colchicine even when the dose was ramped up slowly.

If you can’t tolerate colchicine, a low-dose NSAID like naproxen is the usual alternative. The point is that allopurinol alone, without prophylaxis, sets the patient up for a rough few months that can easily derail the whole treatment plan.

Why Skipping Prophylaxis Is a Risk Factor for Early Recurrence

A study of patients who were started on urate-lowering therapy during an acute gout flare found that about half experienced a recurrent flare within three months. Two factors stood out as strong independent predictors of that recurrence: high levels of C-reactive protein (a marker of systemic inflammation) at baseline, and not receiving prophylactic anti-inflammatory treatment when the urate-lowering drug was started. The odds of recurrence without prophylaxis were roughly eleven times higher than with it.¹⁰ That’s a striking number, and it underscores why anti-inflammatory cover isn’t optional during the initiation period, especially when treatment begins mid-flare.

The Start-Low, Go-Slow Dosing Approach

Most guidelines now recommend starting allopurinol at no more than 100 mg per day (sometimes even lower in people with kidney problems) and increasing by 100 mg every two to five weeks until the target uric acid level is reached. This gentle ramp-up gives the body time to adjust to falling uric acid levels and reduces the severity and frequency of mobilization flares compared to jumping straight to a full dose.

The target for most patients is a serum uric acid level below 6 mg/dL, and for people with visible tophi or frequent flares, some guidelines push for below 5 mg/dL. Reaching that target often requires doses well above the commonly prescribed 300 mg, sometimes 400 to 600 mg or more. The “start low” part is well accepted, but the “keep going until you hit target” part gets overlooked surprisingly often. Many patients stay on 300 mg indefinitely even when their uric acid remains above goal, which means crystal deposits never fully dissolve and flares keep recurring.⁵

What Happens When You Stay at Target Long-Term

The payoff for getting through the rough initiation period is substantial. In a five-year follow-up study of patients on treat-to-target urate-lowering therapy, uric acid levels dropped from a mean of about 500 to 337 micromoles per liter (roughly 8.4 to 5.7 mg/dL). More than 70% of patients were below the target level at the five-year mark. Crystal deposits visible on ultrasound shrank dramatically, with full dissolution of the characteristic “double contour” sign in over 80% of patients and tophus dissolution in more than 60%. Only 16% of patients reported a flare in the preceding year, and those who did tended to have higher uric acid levels and more residual crystal deposits.¹¹

Those numbers illustrate why rheumatologists frame allopurinol as a long-term investment. The first months can feel like the medication is failing, but by the second or third year, crystal deposits are measurably shrinking and flares are becoming rare. By year five, a majority of patients on successful therapy have their disease largely under control. Stopping the drug, however, lets uric acid rise back up and crystals re-form, so allopurinol is typically a lifelong commitment.

HLA-B*5801 Screening Before Starting

A small percentage of people carry a genetic variant called HLA-B*5801 that puts them at sharply elevated risk of a severe and potentially fatal hypersensitivity reaction to allopurinol, including Stevens-Johnson syndrome and toxic epidermal necrolysis. The variant is rare in people of European descent but more common in people of Southeast Asian, Korean, and African American heritage, where the carrier rate can exceed 5%.¹²

The ACR guideline recommends HLA-B*5801 testing before starting allopurinol in patients of Southeast Asian or African American descent. Some guidelines go further and recommend testing everyone regardless of ancestry. The test is a simple blood draw. If you carry the variant, allopurinol is off the table and an alternative drug like febuxostat is used instead. A meta-analysis confirmed a strong association between HLA-B*5801 and allopurinol-induced severe skin reactions, reinforcing the value of screening in higher-risk populations.¹³ If your doctor doesn’t mention this test and you belong to one of these groups, it’s worth asking about.

Febuxostat and Other Alternatives

If allopurinol isn’t an option due to hypersensitivity, intolerance, or failure to reach target despite adequate dosing, febuxostat is the most common alternative. It works on the same enzyme but with a different chemical structure, so HLA-B*5801-related reactions don’t apply. As noted earlier, flare rates during the initiation phase are comparable between the two drugs, so switching to febuxostat won’t spare you the mobilization-flare problem.⁶ Prophylaxis and gradual dose escalation are just as important with febuxostat as with allopurinol.

Another class of urate-lowering drugs, the uricosurics (like probenecid and benzbromarone), work by increasing the kidneys’ excretion of uric acid rather than blocking its production. In a large observational comparison, benzbromarone was associated with a lower incidence of first gout flares than allopurinol in people with asymptomatic hyperuricemia, though the two drugs were being used for slightly different purposes in that study.¹⁴ Uricosurics tend to be second-line choices in most countries due to availability and side-effect considerations, but they remain useful options when xanthine oxidase inhibitors don’t work or can’t be used.

Practical Advice for the Initiation Period

If you and your doctor decide to start allopurinol during a flare, a few things help set realistic expectations and improve your odds of sticking with the treatment:

Keep treating the flare: Allopurinol doesn’t address the acute inflammation. You still need an anti-inflammatory drug (an NSAID, colchicine at acute-attack doses, or a corticosteroid) to manage the current flare while the allopurinol starts working on background uric acid levels.
Expect a bumpy few months: Additional flares during the first three to six months don’t mean the drug has failed. They’re a predictable consequence of crystal deposits breaking up.
Take prophylaxis as prescribed: Low-dose colchicine or a low-dose NSAID alongside the allopurinol for at least three to six months dramatically reduces the number and severity of mobilization flares.
Don’t stop at 300 mg if your uric acid is still high: The dose should be titrated upward until your serum uric acid is consistently below target. Regular blood tests during the escalation period are important.
Don’t quit after a flare: Stopping allopurinol during a flare was once common advice but is no longer recommended. Stopping and restarting repeatedly can cause its own problems, including renewed risk of mobilization flares each time.

Diet and Lifestyle During Allopurinol Initiation

Dietary modifications are sometimes discussed alongside allopurinol initiation, though their role is complementary rather than a substitute for medication. In a case report of a patient with tophaceous gout, a combination of allopurinol at 300 mg daily plus dietary changes (limiting red meat, increasing low-fat dairy products) brought uric acid down to 3.7 mg/dL within three months, with the patient becoming disease-free during that period.¹⁵ A single case doesn’t prove that diet made the difference, but the general principle is sound: reducing purine-rich foods and alcohol intake while on allopurinol helps keep uric acid moving in the right direction. Losing weight, if overweight, can also lower uric acid by a few points independently of medication.

The trap to avoid is thinking that diet alone can replace drug therapy in established gout. Dietary purine restriction typically lowers uric acid by about 1 mg/dL at best. For someone whose baseline is 9 or 10 mg/dL, that barely dents the problem. Diet and lifestyle changes are most useful as an adjunct to allopurinol or another urate-lowering drug, not as a standalone strategy once the disease has declared itself with recurrent attacks or visible tophi.

Why Patients Stop and What Helps Them Continue

Allopurinol adherence is notoriously poor. Surveys consistently find that a large proportion of patients stop the drug within the first year. The reasons are revealing: patients who aren’t motivated by flare prevention, or who don’t trust their doctor’s explanation of why a daily pill is needed, are less likely to start in the first place. Once they begin, forgetfulness is a predictable barrier, but the more destructive one is experiencing a flare while taking the medication and concluding the drug isn’t working.⁷

What helps, according to patient-centered research, is having a clinician who explains the mobilization-flare concept upfront, provides regular uric acid feedback so the patient can see the numbers dropping, and takes early flares seriously by adjusting prophylaxis rather than dismissing the patient’s concerns. Pill-reminder systems help with forgetfulness but don’t address the deeper motivational problem of patients who stop because they’ve lost faith in the drug’s purpose. The patients who stay on allopurinol long enough to benefit are usually those who were told what to expect, believed the drug was necessary, and received responsive care when early setbacks occurred.

1
PubMed Central. The Mechanism of the NLRP3 Inflammasome Activation and Pathogenic Implication in the Pathogenesis of Gout
2
PubMed Central. Allopurinol for pain relief: more than just crystal clearance?
3
PubMed. Early versus Late Allopurinol Initiation in Acute Gout Flare (ELAG): a randomized controlled trial
4
PubMed Central. 2020 American College of Rheumatology Guideline for the Management of Gout
5
The Journal of Rheumatology. What Is Allopurinol Failure and What Should We Do About It?
6
Arthritis & Rheumatology. Gout Flare Risk Similar With Allopurinol vs Febuxostat When Initiating Treat-to-Target ULT
7
PubMed Central. Optimizing adherence to allopurinol for gout: patients’ perspectives
8
PubMed. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis
9
Annals of the Rheumatic Diseases. Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial
10
SpringerLink / Clinical Rheumatology. Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
11
PubMed. Ultrasound-detected crystal depositions and clinical flares dissolve during successful urate-lowering therapy: 5-year follow-up results from the treat-to-target NOR-Gout study
12
PubMed. Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis
13
PubMed Central. Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis
14
PubMed Central. Comparison of Benzbromarone and Allopurinol on Primary Prevention of the First Gout Flare in Asymptomatic Hyperuricemia
15
Karger Publishers (Dubai Medical Journal). Monoarticular Crystal Arthropathy of the Knee: Tophaceous Gout